`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`PFIZER, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`____________
`
`Case IPR2017-01489
`Patent 6,407,213 B2
`____________
`
`DECLARATION OF MARK C. MCLENNAN IN SUPPORT OF
`PETITIONER’S MOTION FOR THE PRO HAC VICE ADMISSION
`
`
`
`PFIZER EX. 1691
`Pfizer v. Genentech
`IPR2017-01489
`
`
`
`Declaration of Mark C. McLennan in Support of
`Petitioner’s Motion for the Pro Hac Vice Admission of Mark C. McLennan
`
`
`I, Mark C. McLennan, do hereby declare:
`
`1.
`
`I am an Associate in the law firm Kirkland & Ellis LLP. Lead counsel
`
`in the inter partes review proceeding is Amanda Hollis, who is a Partner in the law
`
`firm Kirkland & Ellis LLP, and is registered to practice before the PTO and holds
`
`Registration No. 55,629. Backup counsel are (1) Stefan Miller, who is a Partner in
`
`the law firm Kirkland & Ellis LLP, and is registered to practice before the PTO
`
`and holds Registration No. 57,623 and; (2) Karen Younkins, who is an Associate
`
`in the law firm Kirkland & Ellis LLP, and is registered to practice before the PTO
`
`and holds Registration No. 67,554. With respect to the proceeding, I will work
`
`closely with Ms. Hollis, Mr. Miller and Ms. Younkins.
`
`2.
`
`I hold a Bachelor of Science degree in Pharmacology and a Bachelor
`
`of Laws from Monash University, Australia. I also hold a Master of Laws degree
`
`from Columbia Law School.
`
`3.
`
`I have approximately four years of experience as a litigation attorney,
`
`specializing in patent litigation and representing clients in patent litigation matters
`
`in various United States District Courts, and the Court of Appeals for the Federal
`
`Circuit. My experience includes several matters in the life sciences and
`
`pharmaceuticals arts. I have particular experience relevant to the technological and
`
`legal matters at issue in this proceeding, including matters concerning monoclonal
`
`antibody therapies and methods of preparing antibodies, including representing
`
`
`
`1
`
`PFIZER EX. 1691
`Pfizer v. Genentech
`IPR2017-01489
`
`
`
`Declaration of Mark C. McLennan in Support of
`Petitioner’s Motion for the Pro Hac Vice Admission of Mark C. McLennan
`
`Pfizer, Inc. (“Petitioner”) with a number of related matters. I am, therefore, an
`
`experienced patent litigation attorney with particular expertise that is pertinent to
`
`the proceeding. Petitioner desires, and has a need, to be represented in certain
`
`aspects of this proceeding by an experienced patent litigation attorney who has
`
`particular expertise that is relevant to the issues involved.
`
`4.
`
`I am very familiar with U.S. Patent No. 6,407,213, and with the legal
`
`subject matter, technical subject matter, and prior art discussed in the Request for
`
`Inter Partes Review. I have personally reviewed the patent at issue, as well as the
`
`prosecution history, submissions filed in this proceeding, and accompanying
`
`declarations and exhibits. I have been and continue to be actively involved with
`
`strategy and with the factual and technical developments in that matter.
`
`5.
`
`I am a member in good standing of the Bar of the State of New York,
`
`U.S. District Court for the Southern District of New York and the Court of Appeals
`
`for the Federal Circuit.
`
`6.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`7.
`
`I have never had a court or administrative body deny my application
`
`for admission to practice.
`
`8.
`
`I have never been sanctioned or cited for contempt by any court or
`
`administrative body.
`
`
`
`2
`
`PFIZER EX. 1691
`Pfizer v. Genentech
`IPR2017-01489
`
`
`
`Declaration of Mark C. McLennan in Support of
`Petitioner’s Motion for the Pro Hac Vice Admission of Mark C. McLennan
`
`
`9.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
`
`10.
`
`I agree to be subject to the United States Patent and Trademark Office
`
`Code of Professional Responsibility set forth in 37 C.F.R. §§ 11.101 et. seq. and
`
`disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
`
`11.
`
`I have been admitted pro hac vice as counsel in the following
`
`proceedings before the United States Patent and Trademark Office:
`
`• IPR2017-00804 and IPR2017-00805 as counsel for Hospira, Inc.
`
`concerning dosages for treatment with anti-ErbB2 antibodies.
`
`• IPR2017-00737 as counsel for Hospira, Inc. concerning treatment
`
`with anti-ErbB2 antibodies.
`
`12.
`
`I declare that all statements made herein of my own knowledge are
`
`true and that all statements made on information and belief are believed to be true;
`
`and further that these statements were made with the knowledge that willful, false
`
`statements and the like so made are punishable by fine or imprisonment, or both,
`
`under Section 1001 of Title 18 of the United States Code.
`
`
`
`
`
`
`
`
`
`
`
`3
`
`PFIZER EX. 1691
`Pfizer v. Genentech
`IPR2017-01489
`
`
`
`Declaration of Mark C. McLennan in Support of
`Petitioner’s Motion for the Pro Hac Vice Admission of Mark C. McLennan
`
`
`Date: November 2, 2017
`
`Respectfully submitted,
`
`
`
`
`
`
`
`By: /Mark C. McLennan/
`Mark C. McLennan
`Kirkland & Ellis LLP
`601 Lexington Avenue
`New York, NY 10022
`Telephone: (212) 909-3451
`Facsimile: (212) 446-4900
`mark.mclennan@kirkland.com
`
`4
`
`PFIZER EX. 1691
`Pfizer v. Genentech
`IPR2017-01489
`
`